Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of IDegLira vs Components in Healthy Chinese Subjects
NCT03292185Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2017
- Primary completion
- Jan 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin degludec + liraglutide in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the serum insulin degludec concentration time curve and Area under the plasma liraglutide concentration time curve. Started Sep 2017; status: completed.
02
Drugs
insulin degludec + liraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03292185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03292185.